Cost-effectiveness analysis

TENNECO TO INTRODUCE NEW LL BRAKE BLOCK FOR RAIL FREIGHT AT 2022 INNOTRANS

Retrieved on:

水曜日, 6月 29, 2022

Advanced Jurid 847 LL brake block helps reduce noise, lower lifecycle cost and improve operating security

Key Points:

Advanced Jurid 847 LL brake block helps reduce noise, lower lifecycle cost and improve operating security
SKOKIE, Ill., June 29, 2022 /PRNewswire/ -- Tenneco will showcase its new Jurid 847 LL brake block for customers in the rail freight industry at the 2022 InnoTrans in Berlin, Germany (September 20 23, stand 430 / Hall 1.2).
Optimized to reduce the rate of wheel wear and likelihood of costly wheel damage, the advanced Jurid 847 LL brake block helps reduce total Life Cycle Costing (LCC) and helps improve operational security of freight wagons.
The product formulation was derived from Tenneco's UIC-certified organic brake block products which are known to improve in-service wheel life.
In addition to in-house simulation and dynamometer development, the new Jurid 847 LL brake block was extensively evaluated during the UIC in-service tests as part of the homologation process.

Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation

Retrieved on:

金曜日, 5月 7, 2021

Health, Health Economics, Health care quality, Costs, Health informatics, Decision analysis, Colonoscopy, Cost-effectiveness analysis, Incremental cost-effectiveness ratio

Sponsorship of analysis and development of the manuscript was provided by Motus GI.\nThe article, which is titled, "Colonoscopy in poorly prepped colons.

Key Points:

Sponsorship of analysis and development of the manuscript was provided by Motus GI.\nThe article, which is titled, "Colonoscopy in poorly prepped colons.
The full publication can be found at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082895 .\n\xe2\x80\x9cWe are delighted that this cost effectiveness analysis of the Pure-Vu System has been accepted for publication in the respected peer-reviewed journal Cost Effectiveness and Resource Allocation.
Base case costs, sensitivity analysis and incremental cost effectiveness (ICE) were evaluated.
Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report

Retrieved on:

月曜日, 3月 15, 2021

The ICER report determined LUPKYNIS to be more cost-effective across several sub-groups of LN patient populations, including black patients, compared to the general population, which ICER notes could have the potential to reduce historic disparities.

Key Points:

The ICER report determined LUPKYNIS to be more cost-effective across several sub-groups of LN patient populations, including black patients, compared to the general population, which ICER notes could have the potential to reduce historic disparities.
ICERs assessment of LUPKYNIS is consistent with the real-world view of LUPKYNIS value we are hearing during our positive interactions with both physicians and payers during the first two months since our launch, said Peter Greenleaf, Chief Executive Officer of Aurinia Pharmaceuticals.
ICER is an independent non-profit research organization that evaluates the evidence on the clinical and economic value of prescription drugs, medical tests, devices, and health system delivery innovations.
The report will next be evaluated by the ICER Council before the organization issues its final Evidence Report.

Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™ Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER)

Retrieved on:

金曜日, 12月 18, 2020

Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Health, Articles, Health care quality, Health Economics, Costs, ICER, Wavelets, Cost-effectiveness analysis, COVID-19 pandemic, Vicineum™, Non-Muscle Invasive Bladder Cancer, Sesen Bio

We are very pleased with the final ICER report and found the entire process to be transparent, evidence-based and professional, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

Key Points:

We are very pleased with the final ICER report and found the entire process to be transparent, evidence-based and professional, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.
The findings in the ICER report give us confidence in the value and cost-effectiveness of Vicineum.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

NASHNET Announces the Publication of a Cost-Effectiveness Analysis Study in the Leading Journal "Gastroenterology "

Retrieved on:

金曜日, 9月 4, 2020

Articles, Health, Health Economics, Health care quality, Costs, Health informatics, Medical terminology, Quality-adjusted life year, Non-alcoholic fatty liver disease, Cost-effectiveness analysis, Screening, Incremental cost-effectiveness ratio

Researchers developed a Markov model to evaluate the cost-effectiveness of six screening strategies using an incremental, threshold cost-effectiveness ratio of $50,000 per quality-adjusted life year (QALY).

Key Points:

Researchers developed a Markov model to evaluate the cost-effectiveness of six screening strategies using an incremental, threshold cost-effectiveness ratio of $50,000 per quality-adjusted life year (QALY).
Patients suspected to have NAFLD or NASH (NASH stage 2) were prescribed one year of intensive lifestyle intervention (ILI).
Additionally, these screening strategies were found to be cost-effective for T2D patients as young as 40 years of age.
NASHNET is a global Centers of Excellence Network committed to defining and spreading the best practice model forNASHcare delivery.

Bind Personalized Health Plan Outperforms Industry Benchmarks for Total Cost as Members Buy Higher-Quality, Lower-Cost Care

Retrieved on:

水曜日, 8月 19, 2020

Bind Benefits, Inc. released data that shows its health plan outperformed risk-adjusted industry benchmarks for total cost by guiding members to higher-quality, lower-cost care.

Key Points:

Bind Benefits, Inc. released data that shows its health plan outperformed risk-adjusted industry benchmarks for total cost by guiding members to higher-quality, lower-cost care.
View the full release here: https://www.businesswire.com/news/home/20200818005291/en/
Cost per labor and delivery on the Bind plan is 28% lower than the industry benchmark.
Benchmarks also show Bind members buy cost-effective health care:
Members choose less expensive sites of care: Emergency room utilization on a Bind plan is 33% lower than benchmark.
Growing families are saving: Cost per labor and delivery on the Bind plan is 28% lower than the benchmark.

New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

Retrieved on:

月曜日, 11月 11, 2019

Articles, Health, Health Economics, Healthcare quality, Costs, Health informatics, Quality-adjusted life year, Cost-effectiveness analysis, Simulation, Amarin Corporation, Placebo, Cost–utility analysis

The model projected lifetime healthcare costs, CV events, survival and quality-adjusted life-years (QALYs) for icosapent ethyl versus placebo in REDUCE-IT eligible patients.

Key Points:

The model projected lifetime healthcare costs, CV events, survival and quality-adjusted life-years (QALYs) for icosapent ethyl versus placebo in REDUCE-IT eligible patients.
Results: Icosapent ethyl was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs.
In probabilistic sensitivity analysis, >85% of simulations indicated that icosapent ethyl would be cost-effective (i.e., below $50,000 per QALY gained) compared with placebo.
The patient cost and actuarial information used by MedStar in this cost-effective analysis were derived from sources independent of Amarin.

Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting

Retrieved on:

火曜日, 6月 11, 2019

Health, Biotechnology, Clinical trials, Pharmaceutical, Other Health, FDA, General Health, Articles, Health, Health Economics, Healthcare quality, Costs, Health informatics, Cost-effectiveness analysis, Decision analysis, Quality-adjusted life year, ICER, Factoring, Incremental cost-effectiveness ratio

Using only clinical data from the landmark Phase 3 PALISADE trial, ICER found AR101 to be cost-effective well-below ICERs traditional threshold of $100,000-$150,000 per QALY.

Key Points:

Using only clinical data from the landmark Phase 3 PALISADE trial, ICER found AR101 to be cost-effective well-below ICERs traditional threshold of $100,000-$150,000 per QALY.
Additionally, when factoring in the societal perspective, ICER found AR101 to be even more cost-effective compared to avoidance alone.
Stephen Tilles, M.D., Senior Director of Medical Affairs, will represent Aimmune at todays meeting.
This press release concerns AR101, a product candidate that is under clinical investigation, and AR201, a product candidate that Aimmune expects will be under clinical investigation in 2019.

Better Therapeutics to Present Health Economic Data at ISPOR 2019

Retrieved on:

火曜日, 5月 21, 2019

Articles, Health informatics, Health, Healthcare quality, Behavior modification, Digital therapeutics, Cost-effectiveness analysis

SAN FRANCISCO, May 21, 2019 /PRNewswire-PRWeb/ -- Better Therapeutics , a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation of health economic data at the ISPOR 2019 Conference May 18 - 22 in New Orleans.

Key Points:

SAN FRANCISCO, May 21, 2019 /PRNewswire-PRWeb/ -- Better Therapeutics , a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation of health economic data at the ISPOR 2019 Conference May 18 - 22 in New Orleans.
The presentation will include data on the reduction of health resource utilization and cost-effectiveness of Better's digital behavioral intervention in type 2 diabetes and hypertension.
Recognizing there are few existing assessments of the economic benefits of digital therapeutics, Better commissioned health economic and outcomes research (HEOR) to understand the cost-effectiveness of its intervention by analysing both economic and clinical benefit.
Better is beginning to commercialize with health plans, while pursuing regulatory approval of its first prescription digital therapeutic in diabetes.

Institute for Clinical and Economic Review to Expand Deployment of New Health Economics Modeling Platform

Retrieved on:

水曜日, 10月 24, 2018

Health, Healthcare quality, Health Economics, Costs, Healthcare management, Institute for Clinical and Economic Review, Health informatics, Cost-effectiveness analysis, ICER, Medical prescription, Incremental cost-effectiveness ratio

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Policy Analysis Inc. (PAI), a Boston-based health-economics consultancy, today announced that the Institute for Clinical and Economic Review (ICER) will expand its use of PAI's new web-based economic modeling platform, hRo3 ( http://hero3models.info/ ), in its reviews of the clinical and economic value of prescription drugs, medical tests, and other healthcare interventions.

Key Points:

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Policy Analysis Inc. (PAI), a Boston-based health-economics consultancy, today announced that the Institute for Clinical and Economic Review (ICER) will expand its use of PAI's new web-based economic modeling platform, hRo3 ( http://hero3models.info/ ), in its reviews of the clinical and economic value of prescription drugs, medical tests, and other healthcare interventions.
The hRo3 Modeling Platform lets users build cost-effectiveness models for new medicines online, and then share them securely with others as private "live" web apps.
ICER plans to expand use of the platform to support its organization's internal modeling and to further validate models developed by ICER's external partners.
The Institute for Clinical and Economic Review (ICER) ( https://icer-review.org/ )is an independent and non-partisan research organization that objectively evaluates the clinical and economic value of prescription drugs, medical tests, and other health care and health care delivery innovations.